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Abstract
Objectives: While global measures of cardiovascular (CV) risk are used to guide prevention and treatment decisions, these
estimates fail to account for the considerable interindividual variability in pre-clinical risk status. This study investigated
heterogeneity in CV risk factor profiles and its association with demographic, genetic, and cognitive variables.
Methods: A latent profile analysis was applied to data from 727 recently postmenopausal women enrolled in the Kronos
Early Estrogen Prevention Study (KEEPS). Women were cognitively healthy, within three years of their last menstrual period,
and free of current or past CV disease. Education level, apolipoprotein E e4 allele (APOE4), ethnicity, and age were modeled
as predictors of latent class membership. The association between class membership, characterizing CV risk profiles, and
performance on five cognitive factors was examined. A supervised random forest algorithm with a 10-fold cross-validation
estimator was used to test accuracy of CV risk classification.
Results: The best-fitting model generated two distinct phenotypic classes of CV risk 62% of women were ‘‘low-risk’’ and
38% ‘‘high-risk’’. Women classified as low-risk outperformed high-risk women on language and mental flexibility tasks
(p=0.008) and a global measure of cognition (p=0.029). Women with a college degree or above were more likely to be in
the low-risk class (OR=1.595, p=0.044). Older age and a Hispanic ethnicity increased the probability of being at high-risk
(OR=1.140, p=0.002; OR=2.622, p=0.012; respectively). The prevalence rate of APOE-e4 was higher in the high-risk class
compared with rates in the low-risk class.
Conclusion: Among recently menopausal women, significant heterogeneity in CV risk is associated with education level,
age, ethnicity, and genetic indicators. The model-based latent classes were also associated with cognitive function. These
differences may point to phenotypes for CV disease risk. Evaluating the evolution of phenotypes could in turn clarify
preclinical disease, and screening and preventive strategies. ClinicalTrials.gov NCT00154180
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Several known risk factors for the development of vascular
disease have been linked to not only cardiovascular (CV) disease
endpoints, but also to accelerated cognitive decline and prodromal
Alzheimer’s Disease (AD) [1–5]. Despite public awareness
campaigns and the availability of well-established preventive
options, CV disease remains one of the leading causes of death
for women in the United States [6–7]. Menopause-related changes
in hormonal profile may potentiate the increased risk in CV
disease. Postmenopausal women are at higher risk than age-
matched men, possibly due to gonadal failure and reduced
gonadal steroid production [8]. Estrogens play a key role in
maintaining adequate levels of high-density lipoprotein cholesterol
(HDL-C), a positive influential CV health factor and a significant
independent predictor of nitric oxide-dependent coronary vasodi-
lation (as measured by flow-mediated dilation) in healthy
individuals [9–10]. In contrast, elevated plasma levels of low
density lipoprotein cholesterol (LDL-C) contributes to endothelial
dysfunction and progression of coronary heart disease [11–12].
Endothelial dysfunction, often characterized by decreases in
production of nitric oxide, is mediated not only by lipid profile,
but also by other putative CV risk factors such as elevated glucose
and triglyceride levels and high-sensitivity C-reactive protein [13–
14].
The association between these classical CV disease risk factors
and the magnitude of reactive hyperemia in small arteries can be
observed in individuals with no history of CV disease and normal
lipid profile [15]. Findings further suggest that menopause and
aging also are independent risk factors for endothelial dysfunction
in normotensive women [16]. Moreover, predisposing vascular
disease risk factors such as central obesity, unhealthy diet and
physical inactivity may synergistically increase risk for vascular
disease (for example, low serum HDL-C, diabetes, and elevated
blood pressure). Lower education and income are socio-economic
factors often linked to increased risk of vascular disease, especially
in women [17–18]. Genetic characteristics such as the apolipo-
protein E (APOE) gene polymorphism, particularly the presence of
an e4 allele (or APOE4 isoform), are frequently linked, not only to
hyperlipoproteinemia, but also to AD and cognitive impairment in
non-demented adults [8], [19].
The importance of a multifactorial approach to the evaluation
of both traditional and newer markers of vascular risk has been
shown to augment the predictive accuracy of global estimates of
CV risk [1], [20]. Thus there is an important need for increased
understanding of the prevalence of these risk factors as well as their
covariation. However, the assessment of a multiplicity of risk
factors often involves the use of laboratory values with no
‘‘natural’’ cut-off between ‘‘normal’’ and ‘‘abnormal’’ levels
primarily because some of these measurements (e.g., lipid levels)
are continuous. Moreover, the threshold or cut-point at which a
potential risk factor in the continuum of risk exposure can be
considered a ‘‘true’’ risk is a subject of debate [21–22]. For
instance, specific thresholds for arterial hypertension and hyper-
lipidaemia are on an arbitrary dichotomy [23]. It is also possible
that cut-off criteria for conventional vascular risk factors may in
fact vary systematically by gender, race/ethnicity or socio-cultural
background. Indeed, global measures of risk based on a graded
summation of factors, such as Framingham-based risk scores, have
required re-calibration to improve accurate risk estimation in older
women [24] and in ethnic minorities [25]. Moreover, the
interactive influence of these characteristics may give rise to
complex differential effects on health outcomes. Even when the
assessment of vascular disease risk yields results within clinically
‘acceptable’ ranges there can be considerable between- and
within-individual heterogeneity in the measures considered in
the global evaluation of ‘‘risk.’’
Using a finite mixture modeling approach, [26] this study aimed
at elucidating potential phenotypic heterogeneity in risk based on
multiple measures of vascular disease risk obtained at baseline
from a cohort of postmenopausal women enrolled in the Kronos
Early Estrogen Prevention Study (KEEPS) [27]. We hypothesized
that 1) co-variation among multiple manifest vascular disease risk
factors could be fully explained by a discrete latent variable (latent
groups) capturing heterogeneity in the sample and 2) latent group
or class membership will be associated with demographic, racial/
ethnic, genetic, and cognitive function variables.
Methods
Sample Description and Setting
KEEPS and KEEPS-Cog studies were reviewed and approved
by Institutional Review Boards at all nine enrollment sites and at
the University of Wisconsin, the KEEPS Cognitive and Affective
(KEEPS-Cog) coordinating site. IRB numbers for KEEPS
institutions: The central KEEPS and Phoenix KEEPS (IRB
protocol by the Western IRB): STUDY NUM: 1058663 and
WIRB PRO NUM: 20040792KEEPS (main study & cognitive
substudy) #10-02980 and MDBHAS #11-05383. Brigham and
Women’s Hospital (Partners): #2004-P-002144 BWH. Mayo
Clinic: 2241-04. Columbia: IRB#: AAAA-8062. Yale:
0409027022. University of Utah: 13257. Einstein/Montefiore:
04-08-213. University of Wisconsin, Madison: H-2005-0059.
University of California, San Francisco (UCSF): KEEPS (main
study & cognitive substudy) #10-02980. University of Washing-
ton: IRB #26702; VAPSHCS IRB #01048.
All participants provided written informed consent to partici-
pate in the main KEEPS study and in the KEEPS-cog ancillary
study. The ethics committees approved the consent procedure
utilized in the study. Enrollment occurred between August 2005
and July 2008 with final visits completed in 2012.
Data for this study were obtained from the multisite KEEPS
and KEEPS-Cog substudy. The parent study, KEEPS, was a
randomized, blinded, placebo-controlled clinical trial designed to
compare the effect of 48 months of treatment with low-dose oral
conjugated equine estrogen and transdermal estradiol to placebo
on cardiovascular endpoints in recently menopausal women [27–
28]. The KEEPS-Cog ancillary study aimed to evaluate the
potential differential efficacy of the two forms of menopausal
hormone therapy (MHT) on cognitive and mood function.
Participants were recruited from nine sites across the nation.
Exclusion criteria for the trial included the presence of past or
current CV or cerebrovascular disease, uncontrolled hypertension,
and use of lipid lowering medications. Determinations of ‘‘low
risk’’ for CV disease were based on body mass index (BMI), blood
pressure, fasting cholesterol and glucose values, tobacco use, and
assessment of coronary artery calcification (CAC) measured by
computerized tomography (CT). For a more detailed overview of
the KEEPS study design, sample enrollment criteria, and
randomization and data collection procedures, please refer to
the comprehensive descriptions provided in Harman et al. [27]
and Miller et al. [29].
The mixture modeling analysis used baseline (pre-randomiza-
tion) data from 727 postmenopausal women, between the ages of
42 and 58, who were within 3 years of their final menstrual period.
Table 1 presents a summary of the sample characteristics at study
entry. In terms of demographic characteristics, the sample was
predominantly non-Hispanic white (80.5%), averaged 53
Vascular Disease Risk in Postmenopausal Women
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Characteristics (N, Mean 6 SD, Range; unless otherwise noted)
Demographic N Mean 6 SD) Range
Age (years) 727 52.68±2.60) 42 to 58
Years since menopause 725 1.44±0.73) 1 to 3
Self-reported race/ethnicity (N, %) (692)
Asian or Pacific Islander 21(3.03) –
Black/African American 54 (7.80) –
Non-Hispanic White/Caucasian 557 (80.49) –
Hispanic 53 (7.70)
Other 7 (1.01) –
Education (N, %) (717)
Grade school 3 (0.42) –
Some high school 3 (0.42) –
High school diploma or GED 52 (7.25) –
Some college or vocational school 132 (18.41) –
College graduate 293 (40.86) –
Some graduate or professional school 34 (4.74) –
Graduate or professional degree 200 (27.89) –
Apolipoprotein E e4 allele (APOE4) (N, %) (596) –
156 (26.2)
Vascular Disease Risk Factors
Body mass index (BMI) (kg/m
2) 727 26.19±4.31 16 to 35
Waist Circumference (cm) 716 83.2±15.20 57.2 to 256.5
Total Cholesterol (mg/dL) 727 208.10±33.7 122 to 315
Mean systolic blood pressure (sBP) (mm/Hg) 727 117.43±14.90 82 to 189
Mean diastolic blood pressure (dBP) (mm/Hg) 727 75.30±9.22 50 to 113
Mean arterial blood pressure (MAP) [1] 727 89.62±10.31 63.3 to 132.3
Low density lipoprotein-cholesterol (LDL-C) (mg/dL) 727 110.90±27.8- 11 to 194
High density lipoprotein-cholesterol (HDL-C) (mg/dL) 727 72.0±14.60 24 to 129
Triglycerides (mg/dL) 727 87.00±55.90 7.0 to 374
Fasting blood glucose (FBG) (mg/dL) 727 79.60±10.00 55 to 126
Total Framingham Point Score (FPS) 727 4.00±3.19 25t o1 4
Current tobacco use (N, %) (727) –
50 (6.90)
Measures of Vascular Disease
Coronary artery calcification (CAC) volume score 727 1.33±5.18 0 to 50.00
Carotid artery intima-media thickness (CIMT) 727 0.72±0.09 0.53 to 1.17
Clinical - Cognitive Scores
Factor Scores
Global Cognition 662 0.0±0.88 23.06 to 2.54
Verbal Learning & Memory 662 0.0±0.87 22.96 to 2.40
Auditory Attention & Working Memory 662 0.0±0.75 22.73 to 2.09
Visual Attention & Executive Function 662 0.0±0.73 22.15 to 2.01
Speeded Language & Mental Flexibility 662 0.0±0.79 22.50 to 2.50
Mini Mental State Examination (MMSE) 647 29.1±1.40 22 to 30
(1) MAP was estimated as
2dBPzsBP ðÞ
3 .
doi:10.1371/journal.pone.0068741.t001
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minimum of a college degree. Additionally, of those consenting to
DNA testing (N=596), 26% had at least one APOE e4 allele; a
genetic risk marker often associated with adverse changes in
cognitive functioning occurring prematurely during the aging
process, [30–31] CV disorders in middle age, [32–33] and shown
to interact with female gender [34–35]. Most participants (87%)
were entirely free of CAC at baseline. The remaining 13% of the
sample had CAC volume scores ranging from 0.015 to 50.
Selected anthropometric, clinical, serum, and behavioral
indicators of vascular disease risk for the total sample at baseline
are also summarized in Table 1. The mean body mass index
(BMI) was 26.19 kg/m
2 (SD=4.31) with close to 50% of the
sample with a BMI ranging from 26 to 35 kg/m
2, which is
considered overweight or obese as defined by published standards
[36]. Approximately 33% of the sample had a waist circumference
above the cut-off score for female central/abdominal obesity
(.88 cm) among Caucasians in the United States [37]. Waist
circumference measures for the total sample ranged from 57 to
256.5 cm (M=83.2, SD=15.2). A relatively small percentage of
women in the sample (6.9%) self-identified as current smokers.
Although mean values for other vascular disease risk factors shown
in Table 1 were within ‘normal’ reference standards, the lower
(e.g., HDL-C) or upper (e.g., total cholesterol, triglycerides, LDL-
C) limit for the range of measures, in most risk factors, were
slightly beyond the boundaries of ‘clinically desirable levels.
Laboratory Analyses and Anthropometric Measurements
Seven vascular disease risk variables were used as surrogates for
latent class membership in the analysis. These included six absolute
measures (BMI, carotid artery intima-media thickness (CIMT),
LDL-C, fasting blood glucose (FBG), HDL-C, and triglycerides)
and a global average value of risk based on Framingham point
scores (FPS) [38]. All participants underwent venous blood draws
in the morning after at least 12 hours of fasting. Blood samples for
lipid, glucose, and triglycerides levels measurements were sent to
and analyzed by Kronos Science Laboratories (Phoenix, AZ).
Blood pressure readings were taken in the morning at least 30
minutes before the blood draws or weight measurement. CIMT
was measured by high-resolution B-mode ultrasound [39]. FPS
were computed following standard procedures for points assign-
ment and summation described in Wilson et al. [38] from the
following six variables: 1) age, 2) systolic blood pressure, 3) diastolic
blood pressure, 4) smoking, 5) HDL-C, and 6) total cholesterol.
For each of these risk factors, points were assigned according to the
level of associated risk.
Height (cm) and weight (kg) measurements were obtained as
part of KEEPS health examination protocol and BMI was
calculated as weight divided by height squared (kg/m2). Table 2
summarizes the zero-order correlations for the seven vascular
disease risk variables at baseline. As expected, all variables were
significantly correlated with at least one other variable in the set;
with triglycerides and HDL-C having the highest inverse
correlation (r=20.486; p,0.002).
APOE Genotyping
APOE genotype was determined from DNA extracted from
venous blood samples obtained from subjects who gave informed
consent for genetic analysis. Blood samples were collected in
ethylenediaminetetraacetic (EDTA) tubes during participants’
health examination. DNA was amplified by polymerase chain
reaction using specific primers for the APOE gene. The DNA was
then sequenced and analyzed for genotype using the FinchTV
program (Version 1.3; Geospiza, Inc). APOE4, as well as age,
race/ethnicity, and education (as an indicator of socio-economic
status-SES) were modeled as predictors of latent class membership.
Assessment of Cognitive Function
As part of the KEEPS-Cog substudy protocol, 662 participants
were administered a comprehensive neuropsychological test
battery by personnel trained in standardized assessment and
scoring procedures. In order to efficiently analyze the cognitive
functioning of study participants, a total of 25 test variables were
first grouped into cognitive domains based on theoretical
considerations. By summarizing our neuropsychological battery
into cognitive domains, we limited capitalizing on chance
associations in subsequent statistical analyses. These theoretical
groupings were then tested iteratively using confirmatory factor
analyses (CFA) [40]. We used multiple criteria and recommended
thresholds for model selection [41]. These included: 1) compar-
ative fit index (CFI) and Tucker-Lewis index (TLI) greater than
0.95, 2) root mean squared error of approximation (RMSEA) [42]
less than 0.05, and 3) the smallest Bayesian information criterion
(BIC) [43] value. All models were estimated using maximum
likelihood (ML) estimation procedures with standard errors robust
to non-normality of observations. The statistics software R,
Version 2.15.1 (http://cran.r-project.org/) and the package lavaan,
[44] Version 0.4–14, were used to fit the CFA models.
Table 2. Bivariate Correlations for the Vascular Disease Risk Variables at Baseline.
V a r i a b l e 1234567
1 BMI 1
2 CIMT 0.057 1
3 LDL-C 0.157 0.030 1
4 HDL-C 20.336 20.046 20.129 1
5 Triglycerides 0.330 0.073 0.231 20.486 1
6 Fasting Glucose 0.276 20.018 0.068 20.200 0.214 1
7 FPS 0.376 0.152 0.399 20.485 0.458 0.238 1
Correlations greater than the absolute value of r=0.12 were significant using a per-test Sidak-adjusted.
p,0.002 and a family-wise alpha of 0.05.
BMI=Body mass index; CIMT=carotid artery intima-media thickness; LDL-C=Low-density lipoprotein cholesterol; HDL-C=High-density lipoprotein cholesterol;
FPS=Framingham point scores.
doi:10.1371/journal.pone.0068741.t002
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[45] including a final set of 18 test variables sharing a common
underlying construct, provided the best fit to the data. (For a
detailed list of the tests included in the final model and an
illustration of the bi-factor model, see Figure 1 and Table S1.
Table S2 presents a summary of the bi-factor solution. The bi-
factor model included a single broad, general construct or factor
(labeled global cognition) and four specific and distinct factors
uncorrelated with and varying independently of the general or
global cognition factor. The four specific factors were labeled as 1)
verbal learning & memory 2) auditory attention & working
memory, 3) visual attention & executive function and 4) speeded
Figure 1. Bi-factor model for the cognitive baseline data. Eighteen variables from nine tests were used to estimate the model with a global
cognitive factor capturing covariation across all variables and four independent secondary factors explaining specific shared covariations beyond that
shared with other variables.
doi:10.1371/journal.pone.0068741.g001
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modeled as outcomes conditioned upon latent class membership.
Analytical Approach
To examine sample heterogeneity or clustering, we used
multiple vascular disease risk indicators as responses in a finite
mixture modeling approach. As mentioned above, the vascular
disease indicators included: BMI, HDL-C, LDL-C, triglycerides,
FBG, CIMT, and FPS. Since the components of finite mixture
densities are modeled as latent classes, the analysis is also known in
the literature as latent class cluster analysis or latent profile (LP)
analysis [46–47]. Within this modeling framework, the clusters or
‘‘classes’’ are not predefined; they are estimated by the model.
That is, class membership is unobservable and termed latent. It is
reasonable to expect that these indicators will be statistically
dependent; for instance, people with elevated triglyceride levels
also tend to have low HDL-C levels and other conditions such as
obesity and metabolic syndrome. An underlying assumption in the
LP analysis is that indicators are associated because the study
population is comprised of a mixture of subpopulations or classes
[48]. A related underlying principle is that as the number of classes
increases the indicators become more ‘‘homogeneous’’ or ‘‘locally
independent’’ within class. That is, the mutually exclusive classes
derived by the LP model maximize between-group variance and
minimize within-group variance.
To determine sample heterogeneity as a function of vascular
disease risk, we iteratively examined the plausibility of LP models
with one, two, and three-latent class solutions. Models were
compared by examining multiple fit criteria: [49] 1) a comparison
of an c-class solution to an (c+1)-class using a Lo-Mendel Rubin
likelihood-ratio tests (LRT) [50] with the choice of the most
parsimonious model, 2) BIC, and 3) overall model interpretability.
We also used relative entropy as a model selection criterion and
the requirement of at least 5% of the sample in each class. Relative
entropy is a measure of how well the observed indicators predict
class membership with values ranging from 0 to 1 and higher
numbers indicating better classification. The final decision on the
number of classes needed to test the mixture model hypothesis not
only took into account model fit indexes, but also an observed
separation of classes showing structure and response patterns that
were interpretable and meaningful from a theoretical and clinical
perspective.
After rigorous model fit and selection procedures for uncondi-
tional models (no covariates) using the full pre-randomized sample
(N=727), we incorporated four predictors of class membership
into the model, in the same step in which the measurement model
was run, and re-assessed the composition of the classes. The
predictors included: 1) age in years, 2) education level (dichoto-
mized as college degree or higher versus below a college degree), 3)
APOE4 status (carriers of the e3/4 or the e4/4 genotype were
categorized as ‘‘1;’’ the absence of the e4 allele was categorized as
‘‘0’’), and 4) racial/ethnic background (categorized as non-
Hispanic White, non-Hispanic Black, or Hispanic). Other races/
ethnicities were excluded from the analysis performed at this stage,
because the number of participants in these groups was not large
enough to support meaningful comparisons and ensure some
prevalence of the predictor level across classes.
Upon the final model selection, each participant was allocated
to the most probable latent class, that is, the class with the highest
posterior probability of membership. The posterior probability is a
function of the parameters of the LP model, covariates, and the
participant’s vascular risk profile.
Finally, estimated latent classes were modeled as explanatory
variables of cognition in separate analyses; one for each of the five
independent cognitive outcomes. The Wald test, a chi-square
analog of an F-statistic in analysis of variance, was used to assess
the significance of the association between latent classes and
cognitive function. (The full model is illustrated in Figure 2.) A
total of 162 cases in the pre-randomized sample (22%) had at least
one missing data point on the predictors and/or cognitive
outcomes. (Figure 3 shows a schematic diagram of the steps in
the analysis process.).
The nature of each latent class or ‘‘phenotype’’ was examined
by plotting the class-specific estimated mean values against each
vascular disease risk variable across classes and inspecting the
characteristics of the latent class in terms of CV disease risk profile.
To examine the degree to which each class membership could be
impacted by demographic and genetic covariates, we used
multinomial logistic regression. Odds ratios (ORs) were reported
comparing the association between covariates and latent class
membership. All LP models were estimated in MPLUS, Version
6.10, using full information ML methods via the expectation-
maximization (EM) algorithm to handle missing data [51–52]. ML
estimation was performed under the assumption of missing at
random (MAR). [52] We estimated robust standard errors to
account for the non-normality of indicator variables. Results
yielding a p-value less than 0.05 were deemed statistically
significant.
Figure 2. Diagram illustrating the latent profile model. BMI=Body mass index; CIMT=Carotid artery intima-media thickness; LDL-C=Low
density lipoprotein-cholesterol; HDL-C=High density lipoprotein-cholesterol; FSG=Fasting blood glucose.
doi:10.1371/journal.pone.0068741.g002
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Bias due to over-fitting is a common criticism of ‘‘in-sample’’
model selection in latent class modeling. We used a supervised
random-forest (RF) classification algorithm with a 10-fold cross-
validation estimator [53] to assess overall classification accuracy
(or error rate). Latent class membership was modeled as the
outcome conditioned upon vascular risk variables. Details of the
RF procedure are explained elsewhere [53–54]. Briefly, in an
attempt to reduce the bias of a ‘‘single tree’’ prediction of classes,
ntree bootstrap samples are drawn from the total data set and for
each of the samples, a classification tree is grown. The split of each
node in the tree is based on a random sample of predictors. New
data are predicted by aggregating the ntree classification trees (i.e.,
the majority votes for the classification). The accuracy or ‘‘error
rate’’ is estimated by predicting the data not in the bootstrap
sample (generally 1/3 of the sample) using the classification tree
obtained with the bootstrap sample (2/3 of the sample). All these
predictions are aggregated to obtain an estimate of misclassifica-
tion or error rate. In our analysis, we grew a total of ntree=1,000
trees. As part of the algorithm, RF estimates variable importance
measures for each tree through permutation of variable values.
Variable importance is defined as the average increase in error
over all the trees (mean decrease accuracy) grown in the classifier.
The analyses were performed with the randomForest [55] package
in R, Version 2.15.1 (http://cran.r-project.org/).
Results
Latent Profile Analysis
Results for the sequence of unconditional models fitted to the
joint distribution of the seven CV disease risk factors indicated that
a 2-class LP model adequately fit the data. As shown in Table 3,
the unconditional 2-class model had the highest classification
accuracy or Entropy (0.802), the lowest BIC value, and a
Figure 3. Schematic diagram of the principal steps in the analysis. Models were estimated via full information (direct) maximum likelihood
algorithms using all available data.
doi:10.1371/journal.pone.0068741.g003
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classification accuracy was substantially lower (0.684) for the 3-
class model. Despite the rejection of the Lo-Mendell-Rubin LRT
test in favor of the 3-class model (marginal p-value=0.04), the
separation of classes was less interpretable. Including age,
education level, race/ethnicity, and APOE4 as predictors of class
membership (that is, the conditional model) improved overall
model fit and did not change significantly the prevalence of risk in
the two classes. BIC values were lower than those obtained in the
unconditional model and the Entropy for the 2-class model
increased to 0.811. Additionally, the LRT test indicated that a
three-class solution did not represent a significant improvement
over the two-class model (p=0.054). Therefore, a 2-class model
was chosen as the best fitting model.
The patterns of estimated vascular disease risk measures and
posterior probabilities assigned to each individual were used to
label the latent classes. The first class was labeled ‘‘high-risk’’
because participants were more likely to have lower values on
HDL-C and higher values on triglycerides, BMI, LDL-C, FBG,
CIMT, and FPS (see Figure 4). The opposite was observed in the
second class, labeled as ‘‘low-risk.’’ That is, participants tended to
have higher HDL-C levels and lower triglycerides, LDL-C, FBG,
CIMT, and FPS values. The prevalence in the ‘‘high-risk’’ and
‘‘low-risk’’ class was 38% and 62%, respectively. Table 4 shows
the observed and model-estimated means for all the vascular
disease risk variables by latent class. Using an independent samples
t-test, mean differences between groups were highly significant for
all vascular disease risk variables (p-values,0.001).
Table 3. Fit of the Latent Class Profile Models.
Model
No. of Parameters
Estimated Entropy BIC
Lo-Mendell-Rubin
Adjusted LRT (p-value)
Unconditional Model
1-Class 15 – 14,444 –
2-Class versus 1-Class 28 0.802 13,821 0.000
3-Class versus 2-Class 30 0.644 13,824 0.040
Conditional Model
1-Class 20 – 11,177 –
2-Class versus 1-Class 33 0.811 10,719 0.000
3-Class versus 2-Class 40 0.694 10,724 0.054
BIC=Bayesian information criterion; LRT=Likelihood ratio test.
doi:10.1371/journal.pone.0068741.t003
Figure 4. Estimated Mean Vascular Disease Risk for Each Latent Group. BMI=Body mass index; CIMT=Carotid artery intima-media
thickness; LDL-C=Low density lipoprotein-cholesterol; HDL-C=High density lipoprotein-cholesterol; FSG=Fasting blood glucose.
doi:10.1371/journal.pone.0068741.g004
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Age, education, and race/ethnicity were predictive of class
membership (see Table 5). Older age and a Hispanic background
increased the probability of being in the ‘‘high-risk’’ class
(OR=1.140, p=0.002; OR=2.621, p=0.012; respectively). Wom-
en with a college degree or above were more likely to be in the
‘‘low-risk’’ class (OR=0.63, p=0.044). The prevalence rate of
women with at least one APOE-e4 allele was also higher in the
‘‘high-risk’’ class compared with rates in the ‘‘low-risk’’ class
(OR=1.52). However, APOE4 was not predictive of class
membership (p=0.073).
Association between Latent Classes and Cognitive
Function
The Wald test of parameter constraints yielded a statistically
significant association between latent classes and two cognitive
factor scores obtained from the bi-factor solution: 1) speeded
language & mental flexibility (x
2
(1df)=6.995; p=0.008) and 2) the
general global cognition factor (x
2
(1df)=4.786; p=0.029). The
estimated mean cognitive scores were significantly better in the
‘‘low-risk’’ class for speeded language & flexibility (M=0.068) and
global cognition (M=0.772) compared to those obtained in the
‘‘high-risk’’ class (M=20.139; M=20.110, respectively). In a
post-hoc analysis, we estimated the effect of posterior probabilities
of class membership on cognitive performance across all domains
after controlling for group differences in age and education. The
relationship between the probability associated with membership
in the ‘‘high’’ risk class and performance in speeded language and
flexibility tasks remained highly significant (p=0.001). That is, the
higher the probability of being in the ‘‘high’’ risk class, the lower
the score in speeded language and flexibility. However, differences
in global cognition outcomes, as a function of class probabilities
and age and education covariates, were attenuated (p=0.06). In
both analyses, latent classes were not associated with performance
on three specific factors in the bi-factor model, namely, verbal
learning & memory, auditory attention & working memory, and
visual attention & executive function.
Cross-validation through Random Forests
We used the classifications obtained through LP analysis as a
dependent variable conditioned upon vascular risk and predictor
variables to assess the performance of a RF algorithm at predicting
class membership. A 10-fold cross-validation estimator was used to
assess overall error rate. The RF algorithm yielded an estimated
Table 4. Estimated and Observed Within-Class Means and Standard Errors for Vascular Disease Risk Variables From the Two-Class
Model.
Vascular Disease Risk Variables Estimated Within-Class Means
1 Observed Within-Class Means t p-value
Class 1: Low Risk Class 2: High Risk Class 1: Low Risk Class 2: High Risk
Mean SE Mean SE Mean SE Mean SE
BMI 20.324 0.057 0.630 0.073 24.80 3.88 28.97 3.73 12.57 ,0.001
CIMT 20.194 0.051 0.216 0.082 0.70 0.07 0.74 0.10 5.250 ,0.001
LDL-C 20.240 0.064 0.323 0.069 121.89 28.91 138.35 28.23 6.620 ,0.001
HDL-C 0.498 0.055 20.779 0.065 74.13 15.20 51.22 9.80 221.751 ,0.001
Triglycerides 20.510 0.051 0.755 0.086 66.73 25.74 129.26 60.24 14.402 ,0.001
FSG 20.188 0.049 0.361 0.083 87.31 8.46 92.73 9.78 6.718 ,0.001
FPS 20.564 0.059 0.857 0.063 2.16 2.25 6.89 2.14 25.926 ,0.001
Latent Prevalence (Marginal Probability) 62% 38%
1The estimated within-class means represent the mean difference between the vascular disease risk score of that particular class compared with the overall mean.
Estimated means are based on standardized measures.
BMI=Body mass index; CIMT=Carotid artery intima-media thickness; LDL-C=Low density lipoprotein-cholesterol; HDL-C=High density lipoprotein-cholesterol;
FSG=Fasting blood glucose; FPS=Framingham point scores.
doi:10.1371/journal.pone.0068741.t004
Table 5. Conditional Odds Ratios.
Variable
Wald 95%
Confidence Limits
Odds Ratio Lower Upper p-value 95% CLR
High Class on
Education (college degree or higher relative to below college degree) 0.627 0.398 0.987 0.044 2.5
Hispanic (relative to non-Hispanic White) 2.621 1.236 5.56 0.012 4.5
Non- Hispanic Black (relative to non-Hispanic White) 0.951 0.426 2.122 0.902 5.0
Age 1.140 1.05 1.238 0.002 1.2
APOE4 1.521 0.961 2.406 0.073 2.5
Abbreviations: CLR=confidence limit ratio.
doi:10.1371/journal.pone.0068741.t005
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individuals into the ‘‘correct’’ or ‘‘LP-estimated class’’ with
approximately 4% error rate. These results support the previously
obtained solution and the observed pattern of vascular disease risk
measures meaningfully separating individuals into two distinct
groups or phenotypes. Interestingly, the weights assigned to each
vascular disease risk variable ranking their ‘‘importance’’ as
predictors in the RF classifier (see Figure 5) corresponded closely
to the observed separation of classes. For example, the four
variables with the highest importance weights (HDL-C, FPS,
triglycerides, and BMI) also produced the highest separation
between the latent classes illustrated in Figure 4.
Discussion
A latent profile (LP) analysis, using seven clinically-relevant
variables for CV disease risk obtained at baseline from a cohort of
recently menopausal women enrolled in the KEEPS study,
revealed two distinct classes or phenotypes, depicting low versus
high CV risk. The low CV risk group was, as expected, larger,
with 62% of the respondents, while the high risk group comprised
the remaining 38%. Our results supported the hypothesis that
genetic and demographic variables were predictive of the model-
identified classes or phenotypes. An interesting finding is that
latent class membership was significantly associated with perfor-
mance in cognitive tasks. That is, individuals in the low CV risk
group, on average, obtained significantly higher scores particularly
on executive function tasks measuring speeded language and
mental flexibility compared to those in the high CV risk group.
The speeded language and mental flexibility factor score was
composed of tests of letter and category word list generation,
which have been frequently used to investigate the semantic
fluency deficits related to the progression of AD [56–57] and
ischemic vascular dementia [58–59].
Midlife CV risk factors are well-known non-genetic risk factors
for incident AD and cognitive decline. Published studies have also
shown a relationship between higher systolic blood pressure or
total cholesterol and LDL-C concentrations in midlife and
increased risk of cognitive impairment or AD [60–62]. For
example, Knopman et al. [60] found an association between
hypertension and decline in processing speed tasks over a 6-year
period. The relationship between BMI and cognitive function
appears more complex, possibly varying depending on the location
of adiposity. A recent study [63] using baseline data from the
seminal Women’s Health Initiative (WHI) hormone trials cohort
reported an inverse association between BMI and performance on
the Modified Mini-Mental State examination (3MSE); a measure
of global cognitive functioning. Interestingly, this association was
stronger in women with smaller waist to hip ratio (WHR) (,0.78)
and weaker with higher WHR and BMI measurements. These
findings suggested a relationship between BMI and cognitive
function conditioned upon abdominal obesity in cognitively
normal older postmenopausal women. A second study using 4-
year follow-up data from women enrolled in WHI Memory Study
(WHIMS) [64] found significant interactions between BMI,
WHR, and incident cognitive impairment and probable dementia.
That is, in women with BMIs between 20 and 29.9 kg/m
2, central
adiposity (WHR$0.80) was associated with an increased risk of
cognitive impairment and probable dementia. Although the
mechanisms underlying the complex associations between both
indices of obesity and cognitive function are unclear, our study
demonstrated the synergistic role of obesity, as measured by BMI,
in identifying unobserved group heterogeneity.
The present study suggests that even within a relatively healthy
sample of postmenopausal women at ‘‘low’’ CV risk, vascular
disease risk factors exhibit important heterogeneity. The LP
approach captured cross-sectional group differences in CV disease
risk associated with demographic, genetic, and cognitive variables.
To the best of our knowledge, this is the first study investigating
whether model-based CV disease risk profiles or groups, based on
multiple risk criteria, are associated with cognitive function in
recently menopausal women. It is possible that the latent ‘‘at risk’’
group identified by this analysis is capturing women at increased
risk for the vascular pathway to AD. The use of model-based
analytical approaches to identify systematic heterogeneity and
complex ‘‘within-class’’ inter-relationships among multiple bio-
markers of risk may be more informative than using standard
group-based approaches or ‘‘total’’ sample average scores of
vascular risk variables. The accuracy and utility of single estimates
of CV risk, such as FPS, can be greatly enhanced by considering
additional factors that may help explain the considerable
individual variability in risk that may exist in the larger population.
Absolute risk in the Framingham population for a given set of
factors may not be the same as that for all other populations with
differing characteristics such as ethnicity. Therefore, the risk
assigned by the FPS may miss a large number of individuals
destined for CV events. Newer biomarkers such as CIMT and
CAC scores, and both predisposing (e.g., BMI, physical inactivity,
and abdominal obesity) and conditional (e.g., inflammatory
markers and elevated serum triglycerides and lipoprotein) risk
factors may potentially modify the magnitude of risk for
individuals [65–66]. Our findings imply that a mixture-based
approach can have potential to study the relatedness of multiple
risk variables beyond single risk scores measures representing
average values.
Our phenotypes portray a pattern consistent with a large
number of studies showing the varying prevalence of risk factors
and the underlying rates of CV disease events according to age,
education level (as an indicator of SES), and race/ethnicity [67–
72]. For example, in the Framingham study, women with less than
12 years of education had nearly a four-fold higher risk of
developing CV disease than women with higher education level
[69], [71]. The same study also reported a higher incidence of CV
Figure 5. Variable Importance Measures Estimated by Mean
Decreased Accuracy. BMI=Body mass index; CIMT=Carotid artery
intima-media thickness; LDL-C=Low density lipoprotein-cholesterol;
HDL-C=High density lipoprotein-cholesterol; FSG=Fasting blood
glucose; FRAM=Framingham Point scores; TRIG=Triglycerides.
doi:10.1371/journal.pone.0068741.g005
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that found in younger pre-menopausal women. The Cardiovas-
cular Health Study, a longitudinal study designed to examine risk
factors for coronary artery disease in a large population of 5,201
men and women, reported that heavier weight at age 50 (i.e., a
BMI $27) had a stronger association with prevalent CV disease in
women than current weight at age 65 or older [72].
Present findings are also convergent with studies reporting a
higher prevalence of vascular disease risk factors among Hispanics
compared to non-Hispanic Whites [67], [73–76]. Risk factors
observed in these studies included obesity, lower levels of physical
activity, incidence of metabolic syndrome, and lipid abnormalities.
The observed upward prevalence trends in APOE e4 carriers
among women in the ‘‘high risk’’ class in our study is also in
agreement with findings from a large number of studies showing
associations between APOE polymorphisms and cardiovascular
risk and lipid profile phenotypes [8], [77–78]. Other studies have
also demonstrated that a decrease in plasma estrogen levels after
menopause and APOE may jointly affect lipid and triglyceride
levels [79].
A limitation of the current study was the use of a selected
number of CV risk factors in the LP analysis. However, these
measures differentiated between distinct subclinical phenotypes
and suggested a patterning of and unique co-variation in risk
associated with cognitive function and demographic features.
Further studies could explore the reproducibility of the results in
ethnically-varied samples of postmenopausal women. Future
longitudinal studies should also investigate the utility of the
combination of CV disease risk variables used as surrogates for
class membership in this study in predicting not only CV disease,
but also cognitive impairment across multiple domains.
We acknowledge that questions remain regarding the complex
nature of the interrelationships between vascular risk biomarkers
included and not included in the present analysis and their dual
prognostic utility for cognitive decline and CV events. Nonethe-
less, this study highlights the importance of a multifactorial
approach to vascular disease risk. The use of an LP framework for
the identification of empirically-derived qualitative phenotypes of
risk based on a combination of both traditional and newer risk
markers can be extremely useful in defining risk scoring systems
with better prediction accuracy and clinical relevance for
postmenopausal women and ethnic minority groups. Future work
designed to evaluate the evolution of phenotypes could in turn
contribute to the understanding of preclinical disease and the role
of screening and preventive interventions.
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